MARKET

VTYX

VTYX

Ventyx Biosciences, Inc.
NASDAQ
13.94
-0.02
-0.14%
Opening 14:17 02/09 EST
OPEN
13.94
PREV CLOSE
13.96
HIGH
13.96
LOW
13.94
VOLUME
665.54K
TURNOVER
--
52 WEEK HIGH
25.00
52 WEEK LOW
0.7830
MARKET CAP
1.00B
P/E (TTM)
-9.2971
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VTYX last week (0202-0206)?
Weekly Report · 9h ago
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX
Barchart · 4d ago
Largest borrow rate increases among liquid names
TipRanks · 5d ago
Ventyx Biosciences Sets March 3, 2026 Vote on Eli Lilly $14-Per-Share Cash Merger
TipRanks · 6d ago
Weekly Report: what happened at VTYX last week (0126-0130)?
Weekly Report · 02/02 09:38
Weekly Report: what happened at VTYX last week (0119-0123)?
Weekly Report · 01/26 09:39
Ventyx Biosciences call volume above normal and directionally bullish
TipRanks · 01/23 20:45
Ventyx Biosciences Inc. Announces Date for Upcoming Special Meeting of Stockholders
Reuters · 01/22 22:30
More
About VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.

Webull offers Ventyx Biosciences Inc stock information, including NASDAQ: VTYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTYX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VTYX stock methods without spending real money on the virtual paper trading platform.